GPT and Hepatic fibrosis: Because the purpose of this study was to examine the effects of oral semaglutide on a population with suspected MASLD and with a high risk for liver fibrosis, a subject population was established that was assumed to have steatotic liver disease by excluding cases with ALT < 30 (n = 220) based on a recent declaration [9,26].